Journal
VIRULENCE
Volume 9, Issue 1, Pages 262-272Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21505594.2017.1403004
Keywords
human monoclonal antibody; immunodominant staphylococcal antigen A; IsaA; PET; Zr-89; Staphylococcus aureus
Categories
Funding
- Top Institute Pharma projects [T4-213, T4-502]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the U.S. National Institutes of Health [T32 AR067708, R01AR069502]
- CONACyT [169643]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR067708, R01AR069502, K08AR069112] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Staphylococcus aureus infections are a major threat in healthcare, requiring adequate early-stage diagnosis and treatment. This calls for novel diagnostic tools that allow noninvasive in vivo detection of staphylococci. Here we performed a preclinical study to investigate a novel fully-human monoclonal antibody 1D9 that specifically targets the immunodominant staphylococcal antigen A (IsaA). We show that 1D9 binds invariantly to S. aureus cells and may further target other staphylococcal species. Importantly, using a human post-mortem implant model and an in vivo murine skin infection model, preclinical feasibility was demonstrated for 1D9 labeled with the near-infrared fluorophore IRDye800CW to be applied for direct optical imaging of in vivo S. aureus infections. Additionally, (89)Zirconium-labeled 1D9 could be used for positron emission tomography imaging of an in vivo S. aureus thigh infection model. Our findings pave the way towards clinical implementation of targeted imaging of staphylococcal infections using the human monoclonal antibody
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available